Is PAVmed, Inc. overvalued or undervalued?

As of 24 October 2025, the valuation grade for PAVmed, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued given its current metrics, particularly with a P/E ratio of 0, a Price to Book Value of 0.23, and an EV to EBITDA of -0.44. In comparison, Delcath Systems, Inc. is considered expensive with a P/E of 68.06, while Neuronetics, Inc. is classified as risky with a P/E of -5.11, highlighting the relative valuation challenges faced by PAVmed.
The stock has significantly underperformed against the S&P 500, with a year-to-date return of -34.92% compared to the index's 15.47%. This trend continues over longer periods, with a 1-year return of -59.16% versus the S&P 500's 16.90%. Overall, PAVmed, Inc. is currently overvalued based on its financial ratios and performance relative to its peers and the broader market.